Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Epizyme, Inc. stock logo
EPZM
Epizyme
$1.47
$1.47
$0.41
$5.80
$247.44M-0.413.23 million shs7,960 shs
89BIO stock logo
ETNB
89BIO
$10.00
-0.8%
$8.62
$4.16
$11.84
$1.47B1.31.51 million shs1.26 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.27
-1.6%
$1.34
$1.19
$2.04
$1.02B1.393.87 million shs4.28 million shs
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$6.96
+5.9%
$6.64
$4.25
$16.74
$1.01B-1.041.33 million shs1.29 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00%0.00%0.00%0.00%0.00%
89BIO stock logo
ETNB
89BIO
-0.79%-0.50%+5.37%+24.84%+17.37%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-1.55%-4.51%+0.79%-29.44%+4.10%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
+5.94%+1.61%+16.97%-26.27%+32.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
2.8557 of 5 stars
3.53.00.00.03.80.80.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.6151 of 5 stars
3.43.00.04.42.75.00.6
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
4.3606 of 5 stars
3.51.00.04.82.74.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00
N/AN/AN/A
89BIO stock logo
ETNB
89BIO
3.00
Buy$26.43164.29% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75116.54% Upside
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2.92
Moderate Buy$20.50194.54% Upside

Current Analyst Ratings Breakdown

Latest EPZM, WVE, OPK, and ETNB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$18.00
6/11/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/11/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$14.00
5/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/10/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/30/2025
89BIO stock logo
ETNB
89BIO
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/29/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/8/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Epizyme, Inc. stock logo
EPZM
Epizyme
$37.43M6.61N/AN/A($0.54) per share-2.72
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/A$3.34 per shareN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.41$0.07 per share18.75$2.00 per share0.64
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$108.30M9.91N/AN/A$1.37 per share5.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Epizyme, Inc. stock logo
EPZM
Epizyme
-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/A
89BIO stock logo
ETNB
89BIO
-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%8/6/2025 (Estimated)

Latest EPZM, WVE, OPK, and ETNB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
5/1/2025Q1 2025
89BIO stock logo
ETNB
89BIO
-$0.50-$0.49+$0.01-$0.49N/AN/A
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Epizyme, Inc. stock logo
EPZM
Epizyme
N/A
5.35
5.19
89BIO stock logo
ETNB
89BIO
0.06
18.03
18.03
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/A
2.95
2.95

Institutional Ownership

CompanyInstitutional Ownership
Epizyme, Inc. stock logo
EPZM
Epizyme
76.45%
89BIO stock logo
ETNB
89BIO
N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
Epizyme, Inc. stock logo
EPZM
Epizyme
23.40%
89BIO stock logo
ETNB
89BIO
2.60%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
29.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Epizyme, Inc. stock logo
EPZM
Epizyme
250168.33 million128.97 millionOptionable
89BIO stock logo
ETNB
89BIO
40145.98 million141.90 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
240154.13 million109.28 millionOptionable

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Given Outperform Rating at Wedbush
Where WAVE Life Sciences Stands With Analysts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Epizyme stock logo

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

89BIO stock logo

89BIO NASDAQ:ETNB

$10.00 -0.08 (-0.79%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$10.00 0.00 (0.00%)
As of 06/23/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.27 -0.02 (-1.55%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$1.27 0.00 (0.00%)
As of 06/23/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

WAVE Life Sciences stock logo

WAVE Life Sciences NASDAQ:WVE

$6.96 +0.39 (+5.94%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$6.96 0.00 (0.00%)
As of 06/23/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.